Novo Nordisk sees huge rise in first nine months sales

Shares of Danish diabetes care giant Novo Nordisk (NOV: N) were up 6.4% at 852.60 kroner by mid-afternoon today, after it released financial results, showing that sales increased by 26% in Danish kroner and by 16% at constant exchange rates (CER) to 128.9 billion kroner ($17.12 billion) in the first nine months of 2022.

Operating profit increased by 28% in Danish kroner and by 14% at CER to 57.7 billion kroner.

Sales in North America Operations increased by 37% in Danish kroner (22% at CER), and sales in International Operations increased by 16% in Danish kroner (11% at CER) for the nine months.